142 related articles for article (PubMed ID: 22359360)
1. Constant and steady transgene expression of interferon-γ by optimization of plasmid construct for safe and effective interferon-γ gene therapy.
Ando M; Takahashi Y; Nishikawa M; Watanabe Y; Takakura Y
J Gene Med; 2012 Apr; 14(4):288-95. PubMed ID: 22359360
[TBL] [Abstract][Full Text] [Related]
2. Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations.
Magnusson T; Haase R; Schleef M; Wagner E; Ogris M
J Gene Med; 2011 Jul; 13(7-8):382-91. PubMed ID: 21721074
[TBL] [Abstract][Full Text] [Related]
3. Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression.
Mitsui M; Nishikawa M; Zang L; Ando M; Hattori K; Takahashi Y; Watanabe Y; Takakura Y
J Gene Med; 2009 May; 11(5):435-43. PubMed ID: 19291673
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of nuclear delivery of plasmid DNA and transcription by interferon γ: hurdles to be overcome for sustained gene therapy.
Zang L; Nishikawa M; Machida K; Ando M; Takahashi Y; Watanabe Y; Takakura Y
Gene Ther; 2011 Sep; 18(9):891-7. PubMed ID: 21451577
[TBL] [Abstract][Full Text] [Related]
5. Improved anti-cancer effect of interferon gene transfer by sustained expression using CpG-reduced plasmid DNA.
Kawano H; Nishikawa M; Mitsui M; Takahashi Y; Kako K; Yamaoka K; Watanabe Y; Takakura Y
Int J Cancer; 2007 Jul; 121(2):401-6. PubMed ID: 17372909
[TBL] [Abstract][Full Text] [Related]
6. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
7. Controlling the kinetics of interferon transgene expression for improved gene therapy.
Watcharanurak K; Nishikawa M; Takahashi Y; Takakura Y
J Drug Target; 2012 Nov; 20(9):764-9. PubMed ID: 22994266
[TBL] [Abstract][Full Text] [Related]
8. Sustained liver-specific transgene expression from the albumin promoter in mice following hydrodynamic plasmid DNA delivery.
Wooddell CI; Reppen T; Wolff JA; Herweijer H
J Gene Med; 2008 May; 10(5):551-63. PubMed ID: 18330848
[TBL] [Abstract][Full Text] [Related]
9. Interferon-Inducible Mx Promoter-Driven, Long-Term Transgene Expression System of Interferon-β for Cancer Gene Therapy.
Hamana A; Takahashi Y; Nishikawa M; Takakura Y
Hum Gene Ther; 2016 Nov; 27(11):936-945. PubMed ID: 27496321
[TBL] [Abstract][Full Text] [Related]
10. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter.
Yew NS; Przybylska M; Ziegler RJ; Liu D; Cheng SH
Mol Ther; 2001 Jul; 4(1):75-82. PubMed ID: 11472109
[TBL] [Abstract][Full Text] [Related]
11. Increased duration of transgene expression in the lung with plasmid DNA vectors harboring adenovirus E4 open reading frame 3.
Yew NS; Marshall J; Przybylska M; Wysokenski DM; Ziegler RJ; Rafter PW; Li C; Armentano D; Cheng SH
Hum Gene Ther; 1999 Jul; 10(11):1833-43. PubMed ID: 10446923
[TBL] [Abstract][Full Text] [Related]
12. Gene expression and antitumor effects following direct interferon (IFN)-gamma gene transfer with naked plasmid DNA and DC-chol liposome complexes in mice.
Nomura T; Yasuda K; Yamada T; Okamoto S; Mahato RI; Watanabe Y; Takakura Y; Hashida M
Gene Ther; 1999 Jan; 6(1):121-9. PubMed ID: 10341884
[TBL] [Abstract][Full Text] [Related]
13. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression.
Qin L; Ding Y; Pahud DR; Chang E; Imperiale MJ; Bromberg JS
Hum Gene Ther; 1997 Nov; 8(17):2019-29. PubMed ID: 9414251
[TBL] [Abstract][Full Text] [Related]
14. [Optimization of in-vivo gene transfer through regulating biological response to vectors].
Nishikawa M
Yakugaku Zasshi; 2006 Nov; 126(11):1029-37. PubMed ID: 17077609
[TBL] [Abstract][Full Text] [Related]
15. Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization.
Hattori K; Nishikawa M; Watcharanurak K; Ikoma A; Kabashima K; Toyota H; Takahashi Y; Takahashi R; Watanabe Y; Takakura Y
J Immunol; 2010 Mar; 184(5):2729-35. PubMed ID: 20107184
[TBL] [Abstract][Full Text] [Related]
16. CpG-free plasmid expression cassettes for cystic fibrosis gene therapy.
Pringle IA; Hyde SC; Connolly MM; Lawton AE; Xu B; Nunez-Alonso G; Davies LA; Sumner-Jones SG; Gill DR
Biomaterials; 2012 Oct; 33(28):6833-42. PubMed ID: 22727465
[TBL] [Abstract][Full Text] [Related]
17. [The effect of murine interferon-gamma transgene expression on bleomycin-induced pulmonary fibrosis in mice].
Tian GZ; Gao ZC; Xu Y; Gai J; Dong JQ; He QY
Zhonghua Jie He He Hu Xi Za Zhi; 2003 May; 26(5):290-3. PubMed ID: 12892616
[TBL] [Abstract][Full Text] [Related]
18. Interferons inhibit onset of murine cytomegalovirus immediate-early gene transcription.
Gribaudo G; Ravaglia S; Caliendo A; Cavallo R; Gariglio M; Martinotti MG; Landolfo S
Virology; 1993 Nov; 197(1):303-11. PubMed ID: 8212566
[TBL] [Abstract][Full Text] [Related]
19. Transposon-based interferon gamma gene transfer overcomes limitations of episomal plasmid for immunogene therapy of glioblastoma.
Wu A; Oh S; Ericson K; Demorest ZL; Vengco I; Gharagozlou S; Chen W; Low WC; Ohlfest JR
Cancer Gene Ther; 2007 Jun; 14(6):550-60. PubMed ID: 17415381
[TBL] [Abstract][Full Text] [Related]
20. Transgene loss and changes in the promoter methylation status as determinants for expression duration in nonviral gene transfer for factor IX.
Schüttrumpf J; Milanov P; Abriss D; Roth S; Tonn T; Seifried E
Hum Gene Ther; 2011 Jan; 22(1):101-6. PubMed ID: 20677911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
